248.79 (-%)
As of Nov 20, 2024
Source:
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (617) 551-8200 |
| Industry | manufacturing |
| CEO | Yvonne L. Greenstreet, Mbchb |
| Website | http://www.alnylam.com |